|Articles|March 1, 2012
- BioPharm International-03-01-2012
- Volume 25
- Issue 3
BioPharm International, March 2012 Issue (PDF)
Scale-Up of Human Stem Cells
Advertisement
Articles in this issue
almost 14 years ago
Recombinant Albumin Facilitates Formulation Design of Stable Drug Productsalmost 14 years ago
Biosimilar Developers Face a Reference-Product Dilemmaalmost 14 years ago
Communications Advances Present Challenges to Manufacturersalmost 14 years ago
The Drive for Best Practice in Biopharmaceutical Manufacturingalmost 14 years ago
CMOs Face a Kodak Momentalmost 14 years ago
FDA Guides the Way to Biosimilars in the USalmost 14 years ago
Assessing Filling Technologies For Contamination Riskalmost 14 years ago
Putting Risk-Based Decision-Making Where It BelongsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
Charles River Incubator Cohort to Accelerate CGT Development
3
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
4
Developing Next-Gen Cell Lines Using Targeted Integration
5
